This online tool can be used to explore country-level costs of vivax malaria and the potential impact of widespread access to radical cure after G6PD testing. The country-level model complements an analysis of the global economic costs of vivax malaria, bringing together information on the epidemiology of vivax malaria and G6PD deficiency with the costs and to healthcare providers and households. Details on Parameter estimates are available here
The baseline scenario represents the current national policy for the treatment of vivax malaria.
The radical cure scenario represents the costs of implementing widespread radical cure to patients. In this scenario, radical cure is provided to patients presenting to health clinics who are not pregnant, lactating or under 1 year of age, and who test normal for G6PD deficiency using a qualitative rapid diagnostic test (RDT). Treatment of all patients receiving 14-day primaquine is fully supervised to ensure full adherence.